Polypharmacology of Approved Anticancer Drugs

Lade...
Vorschaubild
Dateien
Zu diesem Dokument gibt es keine Dateien.
Datum
2017
Autor:innen
Lisitsa, Andrey
Knight, Richard A.
Melino, Gerry
Antonov, Alexey V.
Herausgeber:innen
Kontakt
ISSN der Zeitschrift
Electronic ISSN
ISBN
Bibliografische Daten
Verlag
Schriftenreihe
Auflagebezeichnung
URI (zitierfähiger Link)
ArXiv-ID
Internationale Patentnummer
Angaben zur Forschungsförderung
Projekt
Open Access-Veröffentlichung
Sammlungen
Core Facility der Universität Konstanz
Gesperrt bis
Titel in einer weiteren Sprache
Forschungsvorhaben
Organisationseinheiten
Zeitschriftenheft
Publikationstyp
Zeitschriftenartikel
Publikationsstatus
Published
Erschienen in
Current Drug Targets. Bentham Science. 2017, 18(5), pp. 534-543. ISSN 1389-4501. eISSN 1873-5592. Available under: doi: 10.2174/1389450117666160301095233
Zusammenfassung

The major drug discovery efforts in oncology have been concentrated on the development of selective molecules that are supposed to act specifically on one anticancer mechanism by modulating a single or several closely related drug targets. However, a bird's eye view on data from multiple available bioassays implies that most approved anticancer agents do, in fact, target many more proteins with different functions. Here we will review and systematize currently available information on the targets of several anticancer drugs along with revision of their potential mechanisms of action. Polypharmacology of the current antineoplastic agents suggests that drug clinical efficacy in oncology can be achieved only via modulation of multiple cellular mechanisms.

Zusammenfassung in einer weiteren Sprache
Fachgebiet (DDC)
570 Biowissenschaften, Biologie
Schlagwörter
Polypharmacology, tyrosine kinase inhibitors, histone deacetylase inhibitors, DNA topoisomerase inhibitors, tamoxifen, drug targets, rational design of multitarget drugs
Konferenz
Rezension
undefined / . - undefined, undefined
Zitieren
ISO 690AMELIO, Ivano, Andrey LISITSA, Richard A. KNIGHT, Gerry MELINO, Alexey V. ANTONOV, 2017. Polypharmacology of Approved Anticancer Drugs. In: Current Drug Targets. Bentham Science. 2017, 18(5), pp. 534-543. ISSN 1389-4501. eISSN 1873-5592. Available under: doi: 10.2174/1389450117666160301095233
BibTex
@article{Amelio2017Polyp-56667,
  year={2017},
  doi={10.2174/1389450117666160301095233},
  title={Polypharmacology of Approved Anticancer Drugs},
  number={5},
  volume={18},
  issn={1389-4501},
  journal={Current Drug Targets},
  pages={534--543},
  author={Amelio, Ivano and Lisitsa, Andrey and Knight, Richard A. and Melino, Gerry and Antonov, Alexey V.}
}
RDF
<rdf:RDF
    xmlns:dcterms="http://purl.org/dc/terms/"
    xmlns:dc="http://purl.org/dc/elements/1.1/"
    xmlns:rdf="http://www.w3.org/1999/02/22-rdf-syntax-ns#"
    xmlns:bibo="http://purl.org/ontology/bibo/"
    xmlns:dspace="http://digital-repositories.org/ontologies/dspace/0.1.0#"
    xmlns:foaf="http://xmlns.com/foaf/0.1/"
    xmlns:void="http://rdfs.org/ns/void#"
    xmlns:xsd="http://www.w3.org/2001/XMLSchema#" > 
  <rdf:Description rdf:about="https://kops.uni-konstanz.de/server/rdf/resource/123456789/56667">
    <dc:creator>Amelio, Ivano</dc:creator>
    <dc:creator>Melino, Gerry</dc:creator>
    <dcterms:title>Polypharmacology of Approved Anticancer Drugs</dcterms:title>
    <void:sparqlEndpoint rdf:resource="http://localhost/fuseki/dspace/sparql"/>
    <dcterms:isPartOf rdf:resource="https://kops.uni-konstanz.de/server/rdf/resource/123456789/28"/>
    <dc:language>eng</dc:language>
    <dcterms:abstract xml:lang="eng">The major drug discovery efforts in oncology have been concentrated on the development of selective molecules that are supposed to act specifically on one anticancer mechanism by modulating a single or several closely related drug targets. However, a bird's eye view on data from multiple available bioassays implies that most approved anticancer agents do, in fact, target many more proteins with different functions. Here we will review and systematize currently available information on the targets of several anticancer drugs along with revision of their potential mechanisms of action. Polypharmacology of the current antineoplastic agents suggests that drug clinical efficacy in oncology can be achieved only via modulation of multiple cellular mechanisms.</dcterms:abstract>
    <dspace:isPartOfCollection rdf:resource="https://kops.uni-konstanz.de/server/rdf/resource/123456789/28"/>
    <dcterms:issued>2017</dcterms:issued>
    <foaf:homepage rdf:resource="http://localhost:8080/"/>
    <dc:date rdf:datatype="http://www.w3.org/2001/XMLSchema#dateTime">2022-02-23T14:42:45Z</dc:date>
    <dc:contributor>Knight, Richard A.</dc:contributor>
    <dc:contributor>Amelio, Ivano</dc:contributor>
    <dc:contributor>Lisitsa, Andrey</dc:contributor>
    <dc:contributor>Antonov, Alexey V.</dc:contributor>
    <dc:creator>Knight, Richard A.</dc:creator>
    <dc:creator>Antonov, Alexey V.</dc:creator>
    <bibo:uri rdf:resource="https://kops.uni-konstanz.de/handle/123456789/56667"/>
    <dc:creator>Lisitsa, Andrey</dc:creator>
    <dcterms:rights rdf:resource="https://rightsstatements.org/page/InC/1.0/"/>
    <dc:contributor>Melino, Gerry</dc:contributor>
    <dcterms:available rdf:datatype="http://www.w3.org/2001/XMLSchema#dateTime">2022-02-23T14:42:45Z</dcterms:available>
    <dc:rights>terms-of-use</dc:rights>
  </rdf:Description>
</rdf:RDF>
Interner Vermerk
xmlui.Submission.submit.DescribeStep.inputForms.label.kops_note_fromSubmitter
Kontakt
URL der Originalveröffentl.
Prüfdatum der URL
Prüfungsdatum der Dissertation
Finanzierungsart
Kommentar zur Publikation
Allianzlizenz
Corresponding Authors der Uni Konstanz vorhanden
Internationale Co-Autor:innen
Universitätsbibliographie
Nein
Begutachtet
Ja
Diese Publikation teilen